{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:38:50Z","timestamp":1788565130599,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Parkinson's disease is the second most common neurodegenerative disorder. Neurochemical studies have implicated metals in pathogenesis of PD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To examine the association of serum iron, transferrin, ferritin, transferrin saturation and UIBC in PD patients and to derive the Discrimination Function with scores of these variables to correctly classify PD cases and healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In the present study, identification of biomarker pool in case-control study involving 79 PD cases and 80 healthy controls were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The results of independent\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test analysis showed that PD cases presented significantly higher (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01) level of transferrin, total iron binding capacity (TIBC), unsaturated iron binding capacity (UIBC) and urea than controls. As only one-third of transferrin is saturated with iron, so the transferrin present in serum has the extra binding capacity (67%), this is called UIBC. Discriminant analysis was performed to determine the factors that best discriminate between the categories of an outcome variables (Disease status = PD and Control) and total of five biochemical independent variables (UIBC, transferrin, iron, transferrin saturation, and copper) were taken into consideration. UIBC has emerged out to be highest discriminating, powerful and independent variable among considered independent variables, which indicates iron deficiency. After development of Discriminant Function (Z) and calculation of discriminant function cut points, a cross-validation analysis of PD cases and controls were conducted. The sensitivity of the developed model was 98.73% and specificity 83.75%. Receiver operating characteristics (ROC) was plotted, and the findings of ROC curve corroborated with the results obtained from discriminant function analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Prospective validation of Discriminant model in large cohort is warranted in future studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_419_20","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T05:35:36Z","timestamp":1617687336000},"page":"234-238","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Evidence-Based Discriminant Analysis"],"prefix":"10.4103","volume":"24","author":[{"given":"Chandra Bhushan","family":"Tripathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Gangania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20240828","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/ana.10483","article-title":"Oxidative stress in Parkinson's disease","volume":"53","author":"Jenner","year":"2003","journal-title":"Ann Neurol"},{"key":"R2-21-20240828","doi-asserted-by":"crossref","first-page":"e83060","DOI":"10.1371\/journal.pone.0083060","article-title":"Assessing plasma levels of selenium, copper, iron and zinc in patients of Parkinson's disease","volume":"8","author":"Zhao","year":"2013","journal-title":"PLoS One"},{"key":"R3-21-20240828","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00702-004-0124-0","article-title":"Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with parkinson's disease","volume":"111","author":"Forte","year":"2004","journal-title":"J Neural Transm"},{"key":"R4-21-20240828","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","article-title":"Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains","volume":"52","author":"Riederer","year":"1989","journal-title":"J Neurochem"},{"key":"R5-21-20240828","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1753-4887.1994.tb01453.x","article-title":"Free radicals and antioxidants: A personal view","volume":"52","author":"Halliwell","year":"1994","journal-title":"Nutr Rev"},{"key":"R6-21-20240828","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s10072-015-2349-0","article-title":"Dietary intake of iron, zinc, copper, and risk of Parkinson's disease: A meta-analysis","volume":"36","author":"Cheng","year":"2015","journal-title":"Neurol Sci"},{"key":"R7-21-20240828","doi-asserted-by":"crossref","first-page":"e1001462","DOI":"10.1371\/journal.pmed.1001462","article-title":"Serum iron levels and the risk of Parkinson disease: A Mendelian randomization study","volume":"10","author":"Pichler","year":"2013","journal-title":"PLoS Med"},{"key":"R8-21-20240828","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.parkreldis.2006.10.002","article-title":"ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control","volume":"13","author":"Koziorowski","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"R9-21-20240828","doi-asserted-by":"crossref","first-page":"855S","DOI":"10.1093\/ajcn\/88.3.855S","article-title":"Role of copper in human neurological disorder","volume":"88","author":"Desai","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"R10-21-20240828","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1471-4159.2006.03907.x","article-title":"Oxidative stress and neurodegeneration: Where are we now?","volume":"97","author":"Halliwell","year":"2006","journal-title":"J Neurochem"},{"key":"R11-21-20240828","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s007020050073","article-title":"Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease","volume":"105","author":"Jim\u00e9nez-Jim\u00e9nez","year":"1998","journal-title":"J Neural Transm (Vienna"},{"key":"R12-21-20240828","first-page":"121","article-title":"Association of Parkinson's disease with altered serum levels of lead and transition metals among South Indian subjects","volume":"51","author":"Kumudini","year":"2014","journal-title":"Indian J Biochem Biophys"},{"key":"R13-21-20240828","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.brainres.2016.06.044","article-title":"Meta-analysis of the association between serum iron levels and Parkinson's disease: Evidence from 11 publications","volume":"1646","author":"Jiao","year":"2016","journal-title":"Brain Res"},{"key":"R14-21-20240828","first-page":"3167","article-title":"Serum iron levels and Parkinson's disease risk: Evidence from a meta-analysis","volume":"9","author":"Wang","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"R15-21-20240828","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.neurobiolaging.2012.05.015","article-title":"Fe and Cu do not differ in Parkinson's disease: A replication study plus meta-analysis","volume":"34","author":"Mariani","year":"2013","journal-title":"Neurobiol Aging"},{"key":"R16-21-20240828","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1212\/WNL.49.3.714","article-title":"Altered systemic iron metabolism in Parkinson's disease","volume":"49","author":"Logroscino","year":"1997","journal-title":"Neurology"},{"key":"R17-21-20240828","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.neuint.2007.10.019","article-title":"Over-expressed human divalent metal transporter 1 is involved in iron accumulation in MES23.5 cells","volume":"52","author":"Xu","year":"2008","journal-title":"Neurochem Int"},{"key":"R18-21-20240828","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3923\/pjbs.2012.1094.1097","article-title":"Serum iron and ferritin in idiopathic Parkinson","volume":"15","author":"Farhoudi","year":"2012","journal-title":"Pakistan J Biol Sci"},{"key":"R19-21-20240828","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/mds.21502","article-title":"Low plasma uric acid level in Parkinson's disease","volume":"22","author":"Annanmaki","year":"2007","journal-title":"Mov Disord"},{"key":"R20-21-20240828","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJM198810203191603","article-title":"Body iron stores and the risk of cancer","volume":"319","author":"Stevens","year":"1988","journal-title":"N Engl J Med"},{"key":"R21-21-20240828","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1196\/annals.1306.019","article-title":"Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases","volume":"1012","author":"Bartzokis","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"R22-21-20240828","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.arr.2004.01.003","article-title":"Does cellular iron dysregulation play a causative role in Parkinson's disease?","volume":"3","author":"Kaur","year":"2004","journal-title":"Ageing Res Rev"},{"key":"R23-21-20240828","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1089\/ars.2009.3018","article-title":"Neuroprotective mechanism of mitochondrial ferritin on 6-hydroxydopamine-induced dopaminergic cell damage: Implication for neuroprotection in Parkinson's disease","volume":"13","author":"Shi","year":"2010","journal-title":"Antioxid Redox Signal"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.AIAN_419_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:23:38Z","timestamp":1787844218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.AIAN_419_20"}},"subtitle":["A New Insight into Iron Profile for the Diagnosis of Parkinson's Disease"],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_419_20","relation":{},"ISSN":["0972-2327"],"issn-type":[{"value":"0972-2327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}